Previous Close | 2.2000 |
Open | 2.2200 |
Bid | 2.2500 x 1000 |
Ask | 2.3000 x 1800 |
Day's Range | 2.1800 - 2.3550 |
52 Week Range | 1.4500 - 6.9800 |
Volume | |
Avg. Volume | 818,309 |
Market Cap | 159.213M |
Beta (5Y Monthly) | 1.87 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2100 |
Earnings Date | Feb 21, 2024 - Feb 26, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.83 |
Key Insights The projected fair value for Codexis is US$4.65 based on 2 Stage Free Cash Flow to Equity Codexis is...
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focused on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and the broader RNA interference (RNAi) therapeutics manufacturing landscape on Friday, December 8, 2023, at 10:00 am ET. The event will feature John Maraganore, PhD, Founder and Former Chief Executive Officer of Alnylam Pharmaceuti
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the 35th Annual Piper Sandler Healthcare Conference, being held November 28-30, 2023, in New York, New York. Management will participate in a fireside chat on Tuesday, November 28, 2023, at 9:30 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, https://ir.codexis.com. A re